Skip to main content

Phase 3 Readout

ABBV: Phase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to

November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
November 1, 2026
Company
AbbVie Inc. (ABBV)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to

ABBV overview →
Indication
Migraine

Other upcoming events for ABBV

Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinatio
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotu
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an